Provided by Tiger Trade Technology Pte. Ltd.

Milliman Healthcare Inflation Plus ETF

20.68
0.0000
Volume:- -
Turnover:239.00
Market Cap:1.55M
PE:- -
High:20.68
Open:20.68
Low:20.68
Close:20.68
52wk High:22.57
52wk Low:19.45
Shares:75.00K
Float Shares:75.00K
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Foghorn Stock Craters as Lilly Scraps Cancer Deal, Forcing 40% Layoffs

Dow Jones
·
1 hour ago

Foghorn Therapeutics Slashes Jobs After Ending Cancer Drug Trials with Ely Lilly

Dow Jones
·
1 hour ago

Lilly Says Foundayo Cuts Predicted 10-Year Type 2 Diabetes Risk 57% in Attain-1 Post-Hoc Analysis

Reuters
·
2 hours ago

Eli Lilly - Foundayo 17.2 Mg Associated with 57% Reduction in Diabetes Risk, 18% in Cardiovascular Risk Versus Placebo

Reuters
·
2 hours ago

Eli Lilly - Foundayo Associated with Reduced Predicted Long-Term Risk of Type 2 Diabetes and Cardiovascular Disease

THOMSON REUTERS
·
2 hours ago

UnitedHealth - 95% of Medicare-Eligible Individuals to Have Access to Hmo Plan in 2027

THOMSON REUTERS
·
2 hours ago

Unitedhealthcare 2027 Medicare Plans Focus on Affordability, Simplicity and a More Connected Healthcare Experience

THOMSON REUTERS
·
2 hours ago

Unitedhealthcare: 2027 Plans Offer $0 Primary Care Visits, $0 Preventive Care, $0 Tier 1 Drug Copays

THOMSON REUTERS
·
2 hours ago

Unitedhealthcare: Introduces 2027 Medicare Advantage Plans; About 90% of Eligible Consumers to Have Access to $0 Premium

THOMSON REUTERS
·
2 hours ago

UnitedHealthcare, Aetna Say 2027 Medicare Advantage Plans to Offer More Limited Provider Networks

Reuters
·
2 hours ago

The Next Frontier for Obesity Drugs Isn't How Much Weight You Lose, but What Kind

Dow Jones
·
13 hours ago

Eli Lilly Says Foundayo Drug Helped Patients Lose Weight in Phase 3 Trial

Dow Jones
·
14 hours ago

Eli Lilly’s Foundayo shows cardiovascular safety in type 2 diabetes study

TIPRANKS
·
15 hours ago

Lilly's Oral Glp-1, Foundayo (Orforglipron), Demonstrated Cardiovascular Safety Alongside Sustained A1c Reduction and Weight Loss in Its Largest and Longest Type 2 Diabetes Study

THOMSON REUTERS
·
15 hours ago

Eli Lilly - Achieve-4: Foundayo Shows 16% Lower Mace-4 and 23% Lower Mace-3 Risk vs Insulin Glargine

THOMSON REUTERS
·
15 hours ago

Eli Lilly - Foundayo Shows Smaller Egrf Reduction and Greater Albuminuria Reduction vs Insulin Glargine

THOMSON REUTERS
·
15 hours ago

Merck, 3M Share Losses Contribute to Dow's 286-Point Drop

Dow Jones
·
17 hours ago

Judge Denies In Part UnitedHealth's Motion to Dismiss CalPERS Suit

MT Newswires Live
·
19 hours ago

Judge Denies in Part UnitedHealth's Motion to Dismiss CalPERS Suit

MT Newswires Live
·
19 hours ago

Sector Update: Healthcare

MT Newswires Live
·
20 hours ago